Mar 05, 2019 / 10:00PM GMT
Operator
It is now my pleasure to turn today's program over to Todd Pettingill, Senior Director, Corporate Development and Investor Relations. The floor is yours.
Todd Pettingill - Ligand Pharmaceuticals Incorporated - Director of Corporate Development
Welcome to today's conference call to discuss Ligand's sale of Promacta royalty to Royalty Pharma. Speaking today for Ligand are John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.
As a reminder, today's call will contain forward-looking statements within the meaning of federal securities laws. These may include, but are not limited to statements regarding intent, belief or current expectations of the company and its management regarding its internal and partnered programs. These statements involve risks and uncertainties, and actual events or results may differ materially from the projections described in today's press release and this conference call. Additional information concerning risk factors and other matters concerning Ligand can be found in Ligand's earnings press release and public periodic
Ligand Pharmaceuticals Inc Announce Sale of Promacta Assets and Royalty to Royalty Pharma Call Transcript
Mar 06, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers